NU.V - NeutriSci International Inc.
| Previous Close | 0.0350 |
| Open | 0.0350 |
| Bid | 0.0300 x 0 |
| Ask | 0.0350 x 0 |
| Day's Range | 0.0350 - 0.0400 |
| 52 Week Range | 0.0350 - 0.1200 |
| Volume | 25,000 |
| Avg. Volume | 85,725 |
| Market Cap | 4.224M |
| Beta (3Y Monthly) | 2.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
The NeutriSci International (CVE:NU) Share Price Is Down 76% So Some Shareholders Are Rather Upset
It's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply...
- GlobeNewswire
NeutriSci Expands Partnership With Cryopharm and Nutritional High
Under the expanded terms, in addition to manufacturing its own product, Marbl Melts™, Cryopharm will also manufacture NeutriSci’s ZenStix™ and Dablets™ utilizing its manufacturing and infusion license at its manufacturing facility in Sacramento, California. Ryan Erving, COO of Cryopharm commented, “We are excited to partner with NeutriSci and Nutritional High for the production and sale of our Marbl Melts, and the Dablet and Zenstix line of products.
- GlobeNewswire
NeutriSci Announces Initial Order From Cryopharm
NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received an initial order from Cryopharm Corporation (“Cryopharm”). NeutriSci licensed its Cryolization technology to Cryopharm for the manufacturing and distribution of buccal and sublingual rapid release consumable products utilizing both CBD and THC molecules. Cryopharm has placed its order for NeutriSci’s core ingredients, which form the basis of the company’s Marbl Melts. In addition to purchasing the core ingredients from NeutriSci, under the licensing terms, Cryopharm will pay NeutriSci a license fee, and a royalty on gross sales.
- GlobeNewswire
NeutriSci and Thai Freeze Dry Join Forces to Develop New Product Line of Cannabis Edibles
The pilot formulation development and testing program to be conducted under this LOI shall focus on creation of test formulations of NeutriSci’s patented technology tablets to be modified through incorporation of TFD’s proprietary technology together with cannabinoids and other ingredients under TFD’s umbrella of products. Testing will be conducted at TFD’s facilities in Chiang Mai, Thailand.
- GlobeNewswire
NeutriSci International Announces Exclusive Distribution Deal
NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy® is pleased to announce effective May 1st, 2019 ANB Canada Inc. (“ANB”) will assume all responsibilities for retail sales and distribution of neuenergy® products in Canada. ANB not only markets, sells, warehouses and distributes consumer OTC brands, but also helps manufacturers in several areas, including generating brand awareness. ANB currently represents the brands of many manufacturers across many different product lines.
- GlobeNewswire
NeutriSci Enters Into LOI With Falcon Technologies Inc. dba Eco-Growth Strategies to Manufacture Sublingual CBD Products
NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.
- ACCESSWIRE
Falcon Technologies aka Eco-Growth Strategies Enters Into LOI With Neutrisci To Manufacture Sublingual CBD Products
SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. ("Falcon") (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet. NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products.
- GlobeNewswire
Neutrisci Announces Product Sales Increase
Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.
- GlobeNewswire
NeutriSci Announces Exclusive Licensing Agreement for CBD Tablet Manufacturing & Distribution With LaSanta Botanicals Ltd.
VANCOUVER, British Columbia, Dec. 06, 2018 -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer.
